Zeke Capital Advisors LLC trimmed its holdings in shares of Celgene Co. (NASDAQ:CELG) by 12.5% during the third quarter, Holdings Channel reports. The firm owned 17,778 shares of the biopharmaceutical company’s stock after selling 2,546 shares during the quarter. Zeke Capital Advisors LLC’s holdings in Celgene were worth $1,765,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of CELG. First PREMIER Bank acquired a new stake in shares of Celgene in the 3rd quarter worth about $26,000. Liberty Wealth Management LLC increased its holdings in shares of Celgene by 212.8% in the 2nd quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 200 shares during the period. Weaver Consulting Group acquired a new stake in shares of Celgene in the 1st quarter worth about $29,000. Massey Quick Simon & CO. LLC acquired a new position in Celgene during the 2nd quarter valued at about $33,000. Finally, Lenox Wealth Advisors LLC acquired a new position in Celgene during the 3rd quarter valued at about $37,000. 72.47% of the stock is currently owned by institutional investors.
In other news, insider Terrie Curran sold 11,338 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $98.27, for a total transaction of $1,114,185.26. Following the completion of the transaction, the insider now owns 13,493 shares in the company, valued at approximately $1,325,957.11. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.39% of the company’s stock.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.17. Celgene had a net margin of 32.24% and a return on equity of 89.93%. The company had revenue of $4.40 billion during the quarter, compared to analyst estimates of $4.22 billion. During the same quarter last year, the firm posted $2.16 EPS. The business’s revenue for the quarter was up 15.4% on a year-over-year basis. On average, analysts anticipate that Celgene Co. will post 9.96 EPS for the current fiscal year.
Several equities analysts have commented on CELG shares. Mizuho cut shares of Celgene from a “buy” rating to a “neutral” rating and lowered their target price for the company from $103.00 to $100.00 in a research note on Monday, August 19th. BidaskClub raised shares of Celgene from a “hold” rating to a “buy” rating in a research note on Tuesday, October 1st. ValuEngine cut shares of Celgene from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 1st. Cowen reissued a “hold” rating and set a $102.00 target price on shares of Celgene in a research note on Tuesday, July 30th. Finally, Zacks Investment Research raised shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 target price on the stock in a research note on Tuesday, July 23rd. One analyst has rated the stock with a sell rating, seventeen have assigned a hold rating and four have assigned a buy rating to the company. Celgene currently has a consensus rating of “Hold” and a consensus price target of $94.60.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Story: Real Estate Investment Trust (REIT) ETF
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.